Background/Aims: The Bretagne-Pays de la Loire cancer observatory, an oncology network created by the French Ministry of Health, is specifically dedicated to assess the use of new targeted anticancer ...therapies in routine practice. In line with the French National Cancer III program, our cancer network set up a real-life cohort, which is independent of the pharmaceutical industry, for patients with colorectal cancer to monitor patient safety and quality of care and promote pharmacovigilance. Materials and Methods: Panitumumab monotherapy was assessed in 243 patients with wild-type Kirsten rat sarcoma who were treated for metastatic colorectal cancer (mCRC) between July 2008 and December 2010 after prior chemotherapy using oxaliplatine and irinotecan. This was a post-European medicine agency marketing (EMA-M) study Results: This study shed light on the best practices, strategic adaptations, clinical results (treatment objective responses, 13%; progression free survival, 2.99 months 2.73-3.15; and overall survival, 6.8 months 5.49-8.38) as well as expected or unexpected (grade 3 or 4:11.5%) secondary effects in the phase IV panitumumab treatment of mCRC. Conclusion: Our results are similar to those by Amado whose phase III study led to obtaining EMA-M for panitumumab and tend to confirm the antitumor activity of this antiepidermal growth factor receptor antibody in the treatment of mCRC. In addition, our results opened avenues to further assessment of panitumumab use as monotherapy as well as its benefit-risk ratio while taking into account the patients' general and clinical characteristics. In 2012, the French National Authority for Health appended these data to the panitumumab transparency committee report. Keywords: Panitumumab, gastrointestinal neoplasm, neoplasm metastasis, survival, safety, aged
Resistance of arthropods to organophosphates and carbamates used as insecticides is mainly due to mutations in genes encoding carboxylesterase or acetylcholinesterase members of the ...alpha/beta-hydrolase fold superfamily of proteins. Mutations that have been described at the molecular level concern 24 species, 31 genes and 32 identical positions in the aligned aminoacid sequences. Seven of these positions are found in more than four species and can be considered as hot spots for mutations. Mutations in one single gene also result in cross resistance to pyrethroids. These figures along with all pieces of information related to these mutations can be recovered from the ESTHER database, dedicated to the alpha/beta-hydrolase fold superfamily (http://bioweb.ensam.inra.fr/esther), through built-in or custom made queries. A sequence alignment of enzymes involved in resistance with highlighted mutated amino acid residues is provided. Selecting one amino acid residue leads to all information about mutations analyzed at this position. Links to the related literature are also available.
PDF
